Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn’s Disease

Abstract

Background and Aims: Fistula relapse occurs in 20-30% of patients with perianal Crohn's disease (PCD) despite optimal medico-surgical management. We aimed in this study to assess the rate of perianal and luminal relapse after surgically induced remission and to determine factors associated with fistula relapse. Methods: Consecutive perianal CD patients who achieved clinical remission after surgery for fistulising PCD from January 2013 to January 2019 were included. The cumulative probabilities of relapse-free survival were estimated using the Kaplan-Meier method. Results: A total of 130 patients were included. Sixty-six of 130 patients received infliximab (IFX) therapy after perianal surgery. After a median follow-up of 62 months (interquartile range [IQR]: 28-117 months), perianal relapse occurred in 30 of 64 (46.9%) nonbiological medication-treated cases and in 14 of 66 (21.1%) cases in the IFX therapy group. The cumulative probabilities of perianal relapse-free survival in patients with nonbiological treatment were 77.1% at 1 year, 54.6% at 3 years, and 30% at 5 years. The rates of survival without perianal fistula relapse in the IFX-treated group were 91.6%, 69.2%, and 59.3% at 1, 3 and 5 years, respectively. In patients treated with IFX after perianal surgery, discontinuation of IFX therapy (odds ratio [OR]=2.43, p=0.036), a penetrating CD phenotype (OR=4.324, p=0.019), and a complex perianal fistula (OR=3.392, p=0.026) were independently associated with perianal relapse in multivariate analysis. Conclusion: Infliximab therapy reduced the risk of perianal relapse after surgical remission in PCD patients compared with nonbiological treatment. However, approximately 40% of patients using infliximab experienced perianal relapse at 5 years, and patients who discontinued use of IFX or experienced a penetrating phenotype or a complex perianal fistula were associated with increased relapse rate.

The use of core descriptors from the ENiGMA code study in recent literature: a systematic review

“…Of these, 166 were included in the full text review. Seventy‐six were further excluded, leaving 90 studies for data extraction [17–106] (Figure 1). Of the 90 studies, there were 53 retrospective studies, 16 prospective observational studies, 16 RCTs, four case series and one cross‐sectional study.…”

Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021

“…If surgery is deemed necessary, surgery should be performed first before simply intensifying medical treatment. However, fistula relapse is common following perianal surgery [ 167 ], and evidence from at least one retrospective review suggests that drug escalation after initial surgery is associated with a significantly reduced likelihood of reoperation [ 168 ]. In patients treated with anti-TNFα therapy who have achieved a symptomatic response, ongoing reassessment is needed to determine if treatment can be maintained at the same level or if the dose of anti-TNFα agent should be increased.…”

Study on the factors influencing the prognosis after perianal abscess surgery

“…The location of the abscess cavity is classified as perianal, ischioanal, intersphincteric and supralevator [ 7 ]. If it cannot be treated in time, it will usually cause the abscess to increase in volume or even rupture, so the pus cannot be discharged completely, leading to the recurrence of the perianal abscess [ 8 ]. In addition, abscesses may also cause systemic infections and spread rapidly, leading to tissue infections and gangrene.…”